SARAH REYNOLDS: Open Payments
NPI 1851722615 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$418 in 14 payments from 11 companies in 2025. Trend: 2023 $145 · 2024 $174 · 2025 $418
Food & beverage: $418
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $103 |
| BioCryst US Sales Co., LLC | 3 | $66 |
| GENZYME CORPORATION | 2 | $59 |
| Novartis Pharmaceuticals Corporation | 1 | $30 |
| AstraZeneca Pharmaceuticals LP | 1 | $28 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| Blueprint Medicines Corporation | 1 | $24 |
| Optinose US, Inc. | 1 | $21 |
| Boston Scientific Corporation | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
Products named: DUPIXENT, ORLADEYO, XOLAIR, FASENRA, NUCALA, AYVAKIT, Xhance, General - Pain Management.
Industry payments across CO — which companies pay providers there.
